NAPLES, Fla., Nov. 06, 2018 — HealthLynked Corp. (OTCQB: HLYK) today announced that Maher Albitar M.D. will be joining the company’s Scientific Advisory Board (SAB).
HealthLynked is an innovative digital healthcare company connecting doctors, patients, and their data. The company has developed a number of software applications that allow patients to connect with the healthcare providers they choose, share medical information and provide personal healthcare recommendations to its members.
The advisory position will assist in expanding the company’s current business objectives, aid in technology advances, navigating the changing healthcare landscape and developing strategic relationships.
Maher Albitar, M.D.
Dr. Maher Albitar is the founder and CEO of Genomic Testing Cooperative, LCA. Dr. Albitar has extensive experience in Anatomic/Clinical Pathology, Hematopathology and Molecular Pathology. He also has extensive business and administrative experience as an executive leader of large laboratories, board member, and director of large scientific and genomic diagnostic studies. Dr. Albitar was the Senior Vice President, Chief Medical Officer and Director of Research and Development at NeoGenomics.
He is credited with transforming NeoGenomics Laboratories from a FISH testing company to a company offering the most sophisticated molecular testing.
Prior to NeoGenomics, Dr. Albitar served as the Medical Director for Hematopathology and Oncology, Nichols Institute, Quest Diagnostics, and Chief R&D for Hematopathology and Oncology for Quest Diagnostics from 2003 to 2010.
From 1991 to 2003, Dr. Albitar held various faculty positions at the University of Texas MD Anderson Cancer Center, including Section Chief of Leukemia Section in Laboratory Medicine and Pathology Department, Director of the Molecular Laboratory and Director of the Hematopathology Fellowship Program. Dr. Albitar was a tenured full professor in Pathology and Leukemia at the time of leaving MD Anderson Cancer Center. Dr. Albitar is certified AP/CP Pathologist with fellowship training in Hematopathology and Molecular Pathology. After his training in Hematopathology, Dr. Albitar spent 4 years in Physician/Scientist training program at the University of Pennsylvania/Howard Hughes Medical Institute and the Department of Genetics.
Dr. Albitar has published more than 300 peer-reviewed papers, book chapters, and review articles. He is the lead inventor on more than 50 different patents and patent applications.
Dr. Michael Dent, CEO stated, “The vision for the HealthLynked SAB is to create a diverse group of healthcare experts that will provide direction in creating the healthcare of the future. I have worked with Dr. Maher during his time at NeoGenomics and his creativity and drive to innovate is amazing. He is a true leader in cutting edge molecular and genetic diagnostics. I am honored to have him on the SAB of HealthLynked.”
About HealthLynked Corp.
HealthLynked Corp. provides a solution for both patient members and providers to improve healthcare through the efficient exchange of medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take more control of their healthcare. Members enter their medical information, including medications, allergies, past surgeries and personal health records, in one convenient online and secure location, free of charge.
Participating healthcare providers can connect with their current and future patients through the system. Other benefits to providers include the ability to utilize the HealthLynked marketing tools to connect with their active and inactive patients to improve patient retention, access more accurate and current patient information, provide more efficient online scheduling and to fill last minute cancellations using our “real time appointment scheduling” all within our mobile application. Healthcare providers pay a monthly fee to access these HealthLynked services.
Forward Looking Statements
Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management, and us are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the “Risk Factors” section of our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q and in other reports we have filed with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov.
Chief Financial Officer
Investor Relations contact:
Hanover International Inc.